An Open-label, Single-arm, Phase 1 Study of the Combination of FMT and Gemcitabine with Nab-paclitaxel As First-line Therapy in Patients with Advanced Pancreatic Ductal Adenocarcinoma.
Latest Information Update: 28 Jan 2025
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic ductal carcinoma
- Focus Adverse reactions
- Acronyms CHASe-PDAC
Most Recent Events
- 23 Jan 2025 Status changed from not yet recruiting to recruiting.
- 06 May 2024 New trial record